ACADIA Pharmaceuticals Inc., a biopharmaceutical company headquartered in San Diego, United States, operates within the Health Care sector, specifically under the Biotechnology industry. The company is publicly traded on the Nasdaq stock exchange, with its shares priced in USD. As of the close of the trading session on January 29, 2026, ACADIA Pharmaceuticals Inc. was valued at $25.13 per share. This price falls within a 52-week range that saw a high of $28.35 on December 22, 2025, and a low of $13.40 on April 8, 2025.
The company’s market capitalization stands at approximately $4.25 billion USD, reflecting its significant presence in the biopharmaceutical landscape. ACADIA Pharmaceuticals Inc. is renowned for its focus on the discovery, development, and commercialization of small molecule drugs aimed at treating central nervous system disorders. The company’s primary therapeutic areas include Parkinson’s disease, schizophrenia, neuropathic pain, and glaucoma, where it seeks to address induced dysfunctions.
Financially, ACADIA Pharmaceuticals Inc. exhibits a price-to-earnings (P/E) ratio of 16.55, indicating a moderate premium over its earnings compared to industry peers. Additionally, the company’s price-to-book (P/B) ratio is 4.95, suggesting a valuation that is moderately higher than its book value. These metrics provide insight into the company’s financial health and market perception.
The company’s initial public offering (IPO) took place on May 27, 2004, marking the beginning of its journey as a publicly traded entity. Despite the volatility observed in its stock price over the past five years, as highlighted in the latest publicly available headline dated January 28, 2026, ACADIA Pharmaceuticals Inc. continues to focus on its strategic objectives in the biopharmaceutical sector.
As of the current date, no further news items have been reported for ACADIA Pharmaceuticals Inc. The company maintains its commitment to advancing treatments for central nervous system disorders, leveraging its expertise in small molecule drug development. For more information, stakeholders and interested parties can visit the company’s official website at www.acadia-pharm.com .
